Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability
By Patrice D Cani, S. Possemiers, T. van de Wiele, Y. Guiot, A. Everard, O. Rottier, L. Geurts, D. Naslain, A. Neyrinck, D. Lambert and 2 more. Gut, 2009
2,426 citations recorded by the source corpus.
Background and aims: Obese and diabetic mice display enhanced intestinal permeability and metabolic endotoxaemia that participate in the occurrence of metabolic disorders. Our recent data support the idea that a selective increase of Bifidobacterium spp. reduces the impact of high-fat diet-induced metabolic endotoxaemia and inflammatory disorders. Here, we hypothesised that prebiotic modulation of gut microbiota lowers intestinal permeability, by a mechanism involving glucagon-like peptide-2 (GLP-2) thereby improving inflammation and metabolic disorders during obesity and diabetes. Methods: Study 1: ob/ob mice (Ob-CT) were treated with either prebiotic (Ob-Pre) or non-prebiotic carbohydrates as control (Ob-Cell). Study 2: Ob-CT and Ob-Pre mice were treated with GLP-2 antagonist or saline. Study 3: Ob-CT mice were treated with a GLP-2 agonist or saline. We assessed changes in the gut microbiota, intestinal permeability, gut peptides, intestinal epithelial tight-junction proteins ZO-1 and occludin (qPCR and immunohistochemistry), hepatic and systemic inflammation. Results: Prebiotic-treated mice exhibited a lower plasma lipopolysaccharide (LPS) and cytokines, and a decreased hepatic expression of inflammatory and oxidative stress markers. This decreased inflammatory tone was associated with a lower intestinal permeability and improved tight-junction integrity compared to controls. Prebiotic increased the endogenous intestinotrophic proglucagon-derived peptide (GLP-2) production whereas the GLP-2 antagonist abolished most of the prebiotic effects. Finally, pharmacological GLP-2 treatment decreased gut permeability, systemic and hepatic inflammatory phenotype associated with obesity to a similar extent as that observed following prebiotic-induced changes in gut microbiota. Conclusion: We found that a selective gut microbiota change controls and increases endogenous GLP-2 production, and consequently improves gut barrier functions by a GLP-2-dependent mechanism, contributing to the improvement of gut barrier functions during obesity and diabetes.
Subfields: Gastroenterology, Molecular Biology, Neurology
View Paper: https://www.semanticscholar.org/paper/ca5a8689238cdd622458898304ceace323111d1c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Gastroenterology
In Molecular Biology
In Neurology
Citations in the corpus
- Chronic Inflammation in Obesity and the Metabolic Syndrome (2010, background): “Cani and collaborators have demonstrated that highfat feeding increases intestinal permeability and the plasma concentration of LPS, that is, metabolic endotoxemia, and that changes in gut microbiota control this metabolic endotoxemia and inflammation [116].”
- Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? (2018, background): “Therefore, glucagon-like peptide-2 may drive improved gut permeability in obese mice.(169) Finally, short-chain fatty acids, such as butyrate and propionate, which are mainly synthesised by gut microbiota, may also contribute to modulating hepatic/peripheral IR and the risk of developing incident T2”
- Beneficial Metabolic Effects of a Probiotic via Butyrate-induced GLP-1 Hormone Secretion* (2013, background): “Changes in the microbiota are correlated with the development of obesity, insulin resistance, and diabetes, presumably because of the ability of the microbes to extract energy from the diet (11), altered fatty acid metabolism within the adipose tissue and liver (13), changes in the levels of gut hor”
- The endocannabinoid system links gut microbiota to adipogenesis (2010, methodology): “…that in vivo colonic CB1 mRNA expression was consistently reduced in gut microbiota models known to improve gut permeability (Figure 1A, B and E) (Cani et al, 2007b, 2008, 2009) and that mice treated with a CB1 receptor antagonist exhibited improved gut permeability (Figures 2C, D and 3), we…”
- Gut Microbiota in Cardiovascular Health and Disease (2017, background): “Thus, lipopolysaccharide and peptidoglycans can trigger numerous downstream signaling processes with host receptors both at the epithelial cell border and within vasculature, particularly under conditions when gut wall barrier function is impaired.(41,42) Gut microbiota can also impact host processe”
- Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders (2015, background): “Moreover, mice treated with prebiotics exhibit improvements in intestinal permeability, tight junction integrity, decreased plasma LPS and cytokine levels in addition to decreased hepatic expression of inflammatory and oxidative stress markers (Cani et al., 2009).”
- Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila (2017, background): “TLR2 has been shown to modulate intestinal homeostasis and host metabolism (Caricilli et al., 2011; Brun et al., 2013), thereby participating in the interactions between microbes and host.”
- Diet-Induced Dysbiosis of the Intestinal Microbiota and the Effects on Immunity and Disease (2012, background): “Obese/overweight children also display increased Enterobacteriaceae compared to children of the same age group (4–5 years) with a normal body-mass index [75].”